Author:
Jatin Vyas (US)
Abstract:
Inhibition of Bruton’s tyrosine kinase (BTK) through covalent modifications of its active site (e.g., ibrutinib [IBT]) is the preferred treatment for chronic B-lymphocyte leukemia and mantle cell lymphoma. However, IBT-treated patients are highly susceptible to invasive fungal infections, including invasive aspergillosis, though the mechanism is poorly understood. Neutrophils are the primary line of defense against invasive fungal infections; therefore, we examined the impact of IBT on primary human neutrophil effector activity against Aspergillus fumigatus. IBT significantly impaired the ability of neutrophils to kill A. fumigatus and potently inhibited reactive oxygen species (ROS) production, chemotaxis, and phagocytosis. Importantly, exogenous TNFα fully compensated for these IBT-associated defects. TNFα also restored the effector activity of neutrophils treated with acalabrutinib and zanubrutinib, newer generation BTK inhibitors. Blocking TNFα with infliximab did not impact ROS production in healthy neutrophils but prevented exogenous TNFα from rescuing the phenotype of IBT-treated neutrophils. The restorative capacity of TNFα was independent of transcription, as ROS production was rescued even after using a transcription inhibitor on IBT-treated neutrophils. Moreover, the addition of TNFα immediately rescued ROS production in IBT-treated neutrophils indicating that TNFα worked through a BTK-independent signaling pathway. Finally, TNFα restored the effector activity of primary neutrophils from patients on IBT therapy, recapitulating our in vitro findings. Altogether, our data indicate that TNFα rescues the block in antifungal immunity imposed by the inhibition of BTK in primary human neutrophils.
Abstract Number: 61
Conference Year: 2024
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Marion Blaize1,2, Guillaume Thizy2, Arnaud Fekkar1,2
2024
59
n/a
-
v
Margherita Bertuzzi (UK)
2024
58
n/a
-
v
Gianluca Vascelli (IT)
2024
57
n/a
-
v
Simon Feys*, Inês Pereira*, Samuel M. Gonçalves, Laura Seldeslachts, Jannes Heylen, Cato Jacobs, Hanne Moon Lauwers, Yves Debaveye, Greet Hermans, Philippe Meersseman, Katrien Lagrou, Marijke Peetermans, Karin Thevissen, Christophe Vandenbriele, Alexander Wilmer, Johan Van Weyenbergh, Frank Van De Veerdonk, Greetje Vande Velde, Cristina Cunha*, Joost Wauters*, Agostinho Carvalho*
* shared first and last authors2024
56
n/a
-
v
François Le Mauff 1,2, Joshua Kerkaert 3, Ira Lacdao 1,2, Marc Yacoub 4, Benjamin Wucher 5, Fabrice Gravelat 1,2, Pierre-Guy Millette 1,2,*, Mario Vergas 6, Lynne P. Howell 6,7, Carey Nadell 5, Robert Cramer 3, J. Stajich 4, Shizhu Zhang 8, Donald C. Sheppard 1,2.
2024
55
n/a
-
v
Fabio Palmieri (CH)
2024
54
n/a
-
v
Uxue Perez-Cuesta (ES)
2024
53
n/a
-
v
Eduardo Pelegri-Martinez (ES)
2024
52
n/a